Supercharged immune cells aim to stop leukemia relapse after transplant
NCT ID NCT06158828
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tests whether giving special 'memory-like' natural killer (NK) cells after a stem cell transplant can help prevent relapse in children and adults with high-risk acute myeloid leukemia (AML). The NK cells come from the same donor as the transplant and are boosted in the lab to be stronger. The trial will check if this treatment is safe and possible to make, and whether it improves survival and reduces side effects like graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
memory-like natural killer (NK) cells
What this could lead to
If successful, this approach could lower the chance of leukemia coming back after a stem cell transplant, improving long-term survival for children and adults with high-risk AML.
What could go wrong
This is an early-phase trial with only 68 participants, so results may not apply to everyone. Risks include graft-versus-host disease, infection, or the NK cells not working as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.